Sterling Medical Devices partners on potential COVID-19 treatment

Moonachie-based Sterling Medical Devices, a provider of custom electro-mechanical and software solutions for the medical device industry, announced on Thursday a partnership with Cedars-Sinai and specialty pharmaceutical company Aytu BioScience Inc. for the development of the Healight Platform Technology as a potential treatment for critically ill patients infected with COVID-19 and other infections.

The Medically Associated Science and Technology (MAST) program at Cedars-Sinai has been working on the patent-pending Healight Platform since 2016.

Recently, MAST enlisted Sterling Medical Devices to help develop a novel endotracheal catheter to emit an ultraviolet UV-A light to critically ill patients on a ventilator.

“We are thrilled to be working side by side with the brilliant teams of Cedars-Sinai and Aytu BioScience on an accelerated schedule to further the development of this potential treatment to fight against COVID-19,” said Dan Sterling, president of Sterling Medical Devices.

“Our recent expansion to a state-of-the art 16,000-square-foot facility has enabled us to significantly increase our capabilities while ensuring our FDA-compliant quality system and clear focus on customer and patient needs remain the keys to our success,” he added.

“The Aytu team is very pleased to be working with Sterling Medical Devices on this important development to potentially aid in the fight against COVID-19,” said Josh Disbrow, chief executive officer of Aytu BioScience.

Disbrow said Sterling has a stellar reputation as a best-in-class medical device development firm with more than 21 years of experience and involvement in over 1,100 projects—none of which failed to receive FDA regulatory approval upon submission.

“Our team is now engaged with our colleagues at Sterling in an effort to finalize the device development, with hope of enabling human use in the near future.”

In Cedars-Sinai’s pre-clinical findings, the Healight Platform Technology’s antiviral and antibacterial properties have shown an impact on eradicating a wide range of viruses and bacteria. Additional data suggest clinical applications across a range of viral and bacterial pathogens. The technology has not yet been tested or used on patients. Upon completion of the catheter, the Healight will move into pilot-scale manufacturing of the device that will be used by Cedars-Sinai for testing in a clinical setting.


Article URL :